company background image
BNTC logo

Benitec Biopharma NasdaqCM:BNTC Stock Report

Last Price

US$12.17

Market Cap

US$274.0m

7D

13.1%

1Y

307.0%

Updated

04 Feb, 2025

Data

Company Financials +

Benitec Biopharma Inc.

NasdaqCM:BNTC Stock Report

Market Cap: US$274.0m

BNTC Stock Overview

A clinical-stage biotechnology company, focuses on the development of novel genetic medicines. More details

BNTC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Benitec Biopharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Benitec Biopharma
Historical stock prices
Current Share PriceUS$12.17
52 Week HighUS$13.29
52 Week LowUS$2.70
Beta0.81
1 Month Change0.58%
3 Month Change16.02%
1 Year Change307.02%
3 Year Change-74.79%
5 Year Change-90.91%
Change since IPO-99.79%

Recent News & Updates

Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition

Jan 20

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Oct 02
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Recent updates

Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition

Jan 20

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Oct 02
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Benitec Biopharma prices of $18M securities offering

Sep 13

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Sep 02

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

Jan 13
We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Sep 30
We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

May 12
Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

Benitec Bio secures $13M capital via equity offering

Apr 28

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

Jan 27
Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Dec 02
How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Shareholder Returns

BNTCUS BiotechsUS Market
7D13.1%1.3%-0.3%
1Y307.0%-2.3%22.7%

Return vs Industry: BNTC exceeded the US Biotechs industry which returned -2.8% over the past year.

Return vs Market: BNTC exceeded the US Market which returned 22.2% over the past year.

Price Volatility

Is BNTC's price volatile compared to industry and market?
BNTC volatility
BNTC Average Weekly Movement10.1%
Biotechs Industry Average Movement11.3%
Market Average Movement6.4%
10% most volatile stocks in US Market18.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: BNTC has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BNTC's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199516Jerel Banksbenitec.com

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

Benitec Biopharma Inc. Fundamentals Summary

How do Benitec Biopharma's earnings and revenue compare to its market cap?
BNTC fundamental statistics
Market capUS$273.95m
Earnings (TTM)-US$20.86m
Revenue (TTM)n/a

0.0x

P/S Ratio

-13.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BNTC income statement (TTM)
RevenueUS$0
Cost of Revenue-US$2.00k
Gross ProfitUS$2.00k
Other ExpensesUS$20.86m
Earnings-US$20.86m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.90
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BNTC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/04 08:15
End of Day Share Price 2025/02/04 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Benitec Biopharma Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Debjit ChattopadhyayGuggenheim Securities, LLC
Raghuram SelvarajuH.C. Wainwright & Co.